DURHAM, N.C., March 19, 2019 — Chimeric antigen receptor (CAR) T-cell therapy shows enormous potential for treating many forms of cancer, including lymphoma, acute myeloid leukemia, and myelodysplastic syndromes. Oncology experts Brian Marks, BSc, DC, Senior Director and Ashley Jones, MSc, Project Lead will discuss these emerging therapies and their potential to unleash the body’s defenses against disease at a live webinar on Tuesday, March 26.
Amazing Science: CAR T and Other Technologies Emerging in Oncology Research, will examine how these advances — some already approved by the FDA — can provide effective alternatives to chemotherapy, radiation, and surgery. Our experts will explore operational and clinical challenges and the pathways that are moving these technologies from laboratory to bedside.
CAR T Cell Therapy and Other Technologies Emerging in Oncology
About Premier Research
Premier Research, a midsize clinical research company, is dedicated to helping biotech, specialty pharma, and device innovators transform life-changing ideas and breakthrough science into new medical treatments.
As a global company, Premier Research specializes in the use of innovative technologies for smart study design and trial management to deliver clean, conclusive data to sponsors.
Whether it’s developing product lifecycle strategies, reducing clinical development cycle times, securing access to patients, navigating global regulations, maximizing the impact of limited rare disease data, or providing expertise in specific therapeutic areas, Premier Research is committed to helping its customers answer the unmet needs of patients across a broad range of medical conditions.